GlassScriptPhysician profile
Heather A Macklem
NPI 1588667117
$4,843.95
in general payments reported to CMS, 2019-2025
35 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,130 · 2020: $424 · 2021: $452 · 2022: $793 · 2023: $751 · 2024: $878 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $890.01 | 2019-2025 | |
| Amgen INC. | $819.34 | 2019-2024 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $462.70 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $429.37 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Allergan, INC. | $221.52 | 2019 | |
| Sunovion Pharmaceuticals INC. | $196.90 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $179.64 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.67 | 2020-2024 | Jardiance |
| Pfizer INC. | $169.04 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $165.84 | 2019-2025 | Airsupra, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $152.39 | 2019-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $129.04 | 2022-2024 | |
| Astellas Pharma US INC | $119.68 | 2019-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $118.89 | 2019-2024 | Gardasil, Gardasil 9, Vaxneuvance |
| Glaxosmithkline, LLC. | $75.32 | 2019-2025 | Shingrix, Trelegy Ellipta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $72.32 | 2023-2024 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $40.31 | 2019 | |
| Sanofi-Aventis U.S. LLC | $40.08 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $38.51 | 2019-2022 | |
| Mylan Specialty L.P. | $36.56 | 2023-2024 | Yupelri |
| Amarin Pharma, INC. | $35.10 | 2020-2022 | |
| Alkermes, INC. | $30.76 | 2019 | |
| Insulet Corporation | $30.64 | 2021 | |
| Exact Sciences Corporation | $28.82 | 2023-2024 | Cologuard Collection Kit |
| Viatris Specialty LLC | $21.35 | 2025 | Yupelri |
| Greenwich Biosciences, INC. | $21.30 | 2019 | |
| Lundbeck LLC | $20.93 | 2025 | Vyepti |
| Ironshore Pharmaceuticals INC. | $19.67 | 2019 | |
| Esperion Therapeutics, INC. | $18.93 | 2021 | |
| Daiichi Sankyo INC. | $17.48 | 2024 | Injectafer |
| Adlon Therapeutics L.P. | $17.15 | 2019 | |
| Amneal Pharmaceuticals LLC | $12.88 | 2023 | Unithroid |
| Vyera Pharmaceuticals, LLC | $12.62 | 2019 | |
| Sanofi Pasteur INC. | $12.39 | 2019 | |
| Mdd US Operations, LLC | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Macklem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.